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Reduced duration mismatch negativity in
adolescents with psychotic symptoms: further
evidence for mismatch negativity as a possible
biomarker for vulnerability to psychosis
Jennifer R Murphy1,2, Caroline Rawdon1, Ian Kelleher2, Deirdre Twomey2, Patrick S Markey2, Mary Cannon2,3*†
and Richard AP Roche1†
Abstract
Background: Deficits in the mismatch negativity (MMN) and P3a components are the most reliable and robust
findings in schizophrenia. These abnormalities have also been recently documented in individuals clinically at risk
for psychosis, indicating that the MMN may be a potential biomarker for psychosis. However, the at risk samples
included in MMN studies are characterised by pre-existing clinical symptomatology and significant functional
decline which are related to MMN amplitude. These factors may be potential confounds in determining whether
deficient MMN is present prior to clinical manifestation of the disorder. Therefore, investigating the MMN in the
extended psychosis phenotype comprising adolescents with psychotic symptoms from the general population may
provide important information on whether abnormal MMN is apparent in the earliest stages of risk.
Methods: Thirty six adolescents completed a duration deviant MMN task. Fourteen adolescents with psychotic
symptoms comprised the at risk group and 22 with no psychotic symptoms comprised the Controls. The task
consisted of 85% standard tones (25 ms) and 15% deviant tones (50 ms). The groups were compared on MMN and
P3a amplitude and latency across frontocentral and temporal electrodes.
Results: Adolescents with psychotic symptoms were characterised by a reduction in MMN amplitude at frontal and
temporal regions compared to the controls.
Conclusions: This is the first study to demonstrate impaired auditory discrimination for duration deviant tones in
nonclinical adolescents with psychotic symptoms. These findings suggest that MMN amplitude may be a possible
biomarker for vulnerability to psychosis.
Keywords: MMN, Mismatch negativity, Psychotic symptoms, Schizophrenia, Psychosis
Background
Disturbances in sensory information processing are
considered to be important pathophysiological mechanisms
underlying the development of psychosis [1]. Electro-
physiological markers of these impairments have been
proposed as potential biomarkers for schizophrenia.
In particular, reduced amplitude of the duration devi-
ant mismatch negativity (MMN) component is one of
the most robust and reliable findings in schizophre-
nia [2].
Mismatch negativity is an automatic neurophysio-
logical response to a deviant auditory stimulus that is
interspersed with a series of standard auditory stimuli
[3,4]. A deviant stimulus may differ on a range of audi-
tory dimensions, such as frequency (pitch), duration, in-
tensity or location [5,6]. The MMN waveform is an early
negative ERP that is maximal over frontocentral areas of
the scalp and peaks between 100-200 ms. MMN tasks
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are usually passive and undemanding, and the MMN
can be elicited without the participant consciously
attending to the auditory stimuli [7,8]. MMN is therefore
an index of the brain’s ability to extract potentially rele-
vant information from an irrelevant background [9].
Multiple MMN generators have been reported in the
auditory cortices and in the prefrontal cortex as part of a
distributed fronto-temporal network subserving change
detection and attentional switching [10-13].
Studies examining the MMN in chronic patients with
schizophrenia [2,14,15], first episode patients [9,16], pro-
dromal individuals [1,17,18] and those genetically at risk
[19-23] have reported reductions in MMN amplitude,
particularly to duration deviants. Bodatsch et al. [1]
found that reduced duration MMN amplitude distinguished
between at risk individuals who converted to psychosis
from those who did not. Shin et al. [18] also reported the
presence of duration MMN deficits in at risk individuals,
regardless of conversion. However, not all studies have
found deficient MMN as normal mismatch negativity has
been reported in unaffected family relatives of patients
with schizophrenia [24,25] and also in first episode
patients [25,26]. MMN latency findings are inconsistent in
schizophrenia studies as some have found delayed latency
[27], whereas others have reported shortened [28] or nor-
mal MMN latency [29].
At frontocentral electrodes, the MMN wave is often
followed by a positive-going ERP component peaking be-
tween 250-300 ms [7]. This early P300 component (i.e.
P3a) is an automatic process which is thought to reflect
an involuntary attention orienting response to a novel
stimulus [7,19,30,31]. P3a amplitude in MMN studies is
reduced in patients with schizophrenia and also in first
episode psychosis [9].
Epidemiological research over the past decade has
demonstrated that psychotic symptoms are far more
prevalent in the population than actual psychotic dis-
order [32]. A recent meta analysis of population studies
showed that 17% of children and 7.5% of adolescents re-
port psychotic symptoms [33]. These young people have
been shown to share a wide range of risk factors with
schizophrenia patients [34] and longitudinal research
has demonstrated an increased risk of psychotic disorder
in adulthood [35,36]. For these reasons, this population
has been considered to represent an ‘extended psychosis
phenotype’ [37] and researchers have advocated studying
aetiological and risk factors for psychosis in this wider
phenotype [38,39] including underlying genetic and bio-
logical factors [40], as opposed to the ‘narrow’ clinical
phenotype of schizophrenia. This approach allows inves-
tigation of the earliest risk factors associated with psych-
osis while excluding potential confounds such as disease
chronicity, medication effects and other illness related
factors.
While there has been a great deal of clinical research on
the extended psychosis phenotype to date, there has been
limited neurobiological research on this population.
Jacobson et al. [41] demonstrated a fronto-temporal dys-
function in adolescents with psychotic-like experiences
compared to a control group and Laurens et al. [42], mean-
while, found electrophysiological evidence for disrupted
error monitoring in adolescents with psychotic-like
experiences from a community sample. This is the first
study to investigate the MMN component in adolescents
with psychotic symptoms in a community based setting.
As the MMN possesses a relatively high specificity for
schizophrenia, the investigation of this component in at
risk individuals may increase our understanding of the sen-




Participants were recruited from the larger Adolescent
Brain Development Study (see Kelleher et al. [43] for
details). In brief, adolescents aged 11–13 years were
recruited from primary (junior) schools in counties
Kildare and Dublin and invited to compete a symptom
survey in the classroom and attend for clinical interview.
Written consent was obtained from both the participant
and their parent or guardian and assent was obtained
from the adolescents before the study commenced.
Following the clinical interview adolescents with psych-
otic symptoms and control adolescents were sampled
from the population-based study and invited to attend
National University of Ireland, Maynooth for the Mis-
match Negativity Study.
Thirty six adolescents aged 11–13 years agreed to take
part in this EEG study comprising 14 with psychotic
symptoms (the At-Risk group) and 22 without psychotic
symptoms (the control group). All participants had nor-
mal hearing and had no previous brain injuries or
neurological disorders. No participants were on any
medication at the time of testing or had any family his-
tory of psychotic illness. Ethics approval was obtained
from the ethics committees in the National University of
Ireland, Maynooth and in Beaumont Hospital, Dublin 9
(ref no. 06/21).
Assessment of psychotic symptoms
Psychotic symptoms were assessed using the Schedule
for Affective Disorders and Schizophrenia for School
Aged Children, Present and Lifetime versions (K-SADS-
PL) [43]. The K-SADS-PL is designed to measure the se-
verity of symptomatology reported by children and
adolescents, and to assess current and past episodes of
psychopathology according to DSM-III-R and DSM-IV
criteria. Children and parents were interviewed separately,
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both answering the same questions about the child. The
psychosis section of the K-SADS was used to assess the
participants’ psychotic symptoms (hallucinations and
delusions) [44]. All interviewers recorded extensive notes
of potential psychotic phenomena in this section of the
interview and a clinical consensus meeting was held
following the interviews. Auditory hallucinations that were
deemed as clinically significant included voices commenting
on behaviour, a voice giving commands, voices conversing,
whispering voices and voices at varying volumes where
the words cannot clearly be distinguished by the indi-
vidual. Clinically significant delusions included feelings
of being watched, unfounded ideas that others are
saying negative things about the individual (which are
distinguished from paranoia and self-consciousness), and
a belief that ghost is communicating directly with the
individual.
MMN paradigm
Participants were presented with 1200 auditory stimuli,
of which 1020 (85%) were standard tones of 1000 Hz
presented at 25 ms (5 ms rise/fall) and 180 (15%) deviant
tones of 1000 Hz at 50 ms (5 ms rise/fall time). The
interstimulus interval was 300 ms. Stimuli were
presented through the computer speakers at 80 dB,
while participants were asked to ignore the sounds and
look at a fixation point located in the centre of the com-
puter screen. The task consisted of three experimental
blocks of 400 stimuli each with a break of 5 seconds be-
tween each block. No motor response or stimulus evalu-
ation was required for the task.
ERP recording
EEG data were recorded using silver/silver chloride
electrodes (Brain Vision©) at 64 electrode sites
positioned according to the extended international 10–
20 system of electrode placement. Electrodes were
attached to an elastic electrode cap (Easy Cap©) which
was fastened with a chin strap. Horizontal eye
movements (HEOG) were recorded from electrodes
positioned at the outer canthus of each eye. Vertical eye
movements (VEOG) were recorded from electrodes
located above and below the left eye. The reference elec-
trode was placed on the nasion of the nose. Skin was
lightly abraded to maintain an impedance level below
10kΩ. The EEG signal was amplified (Brain Vision©)
with a bandpass filter of 0.16-100 Hz and a gain of 1000.
EEG data were digitised at a sampling rate of 500. The
conversion rate was 2000 Hz per channel and the range
was 150 mV. Filters were set at a low cut off of 0.53 Hz
and a high cut off of 30 Hz. Recordings were notch
filtered offline at 50 Hz.
ERP data
Blinks were averaged offline and an EOG automatic
artifact rejection algorithm was applied to the data
[45,46]. Epochs of 50 ms prestimulus to 500 ms post-
stimulus were analysed and baseline corrected to the
interval −50 to 0 ms. Mismatch negativity was measured
from a difference waveform obtained by subtracting the
standard tone ERP waveforms from the deviant tone
ERP waveforms. MMN amplitude and latency were
measured as the most negative data point within the
80–130 ms latency window, post-stimulus onset. Based
on visual inspection of grand averaged waveforms (see
Figure 1), MMN amplitude and latency was obtained for
each group (Controls, At risk) and condition (Standard,
Deviant) over 12 frontocentral electrode sites (FP1, FPz,
FP2, F1, Fz, F2, FC1, FCz, FC2, C3, Cz, C4). As the
MMN is also detected at mastoid areas with reversed
polarity in a nose referenced montage, ERPs were
recorded over left and right temporal electrode sites
(TP9 and TP10) which were positioned over the mastoid
areas (see Table 1). Mean amplitude of the subsequent
P3a component was also measured over a latency of
150-290 ms at central electrodes Fz and Cz. The average
number of trials (M, SD) accepted for the standard and
deviant tones, respectively, were 996.68 (53.67); 171.81
(9.56) for the Controls and 918.78 (136.59); 163.00
(24.05) for the at risk. A 2×2 analysis of variance
(ANOVA) verified that there were no group differences
in the number of trials accepted [F (1, 34) =2.303,
p=.138].
Statistical analyses
Statistical analyses were conducted with SPSS for
Windows 17.0. Chi-square was employed to compare
the at risk and control groups on demographic variables,
including age, sex and socioeconomic status (SES). The
participants’ socioeconomic status was defined by their
parent’s occupations, assessed with the Irish Social Class
Scale obtained from the national Central Statistics
Office. Mixed factorial ANOVA compared the groups on
MMN amplitude and latency. A 2×4 analysis of variance
(ANOVA) was conducted where the between groups fac-
tor was Group (At risk, Control), and Region (Frontal
polar, Frontal; Frontocentral and Central) served as the
within groups factor. A subsequent 2×2 ANOVA was
also conducted where the between groups factor was
Group (at-risk, controls) and the within groups factor
was Laterality (left TP9, right TP10). A 2×2 ANOVA
compared the groups on P3a amplitude and latency at
electrode sites Fz and Cz. An alpha value of p=0.05 was
used for statistical significance and Greenhouse Geisser
correction was reported when the assumption of spher-
icity was violated. Bonferroni corrected t-tests were
performed to further examine any main and interaction
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Figure 1 MMN and subsequent P3a activity across frontocentral scalp regions of the controls (blue) and the at risk (red) groups and
reversed MMN/P3a polarity at the left and right temporal sites.
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effects. Cohen’s d effect sizes were also calculated to des-
cribe the magnitude of any group differences.
Results
The MMN/P3a waveforms at frontocentral and temporal
electrodes for each group are displayed. The at risk
and control groups did not differ significantly on
demographic variables age, sex, handedness and
socioeconomic status (see Table 2). For mean amplitude
measures, a 2×4 ANOVA with Group (At risk, Controls)
as the between subjects factor with Region (frontal polar,
frontal, frontocentral and central) as the within groups
factor revealed a main effect of Group [F (1, 34) = 6.235,
p = .018]. An interaction effect of Region*Group [F (3,
102) = 5.091, p= .014] was also found. Follow up ana-
lyses compared the groups at each region and revealed
reduced mean MMN amplitude in the at risk group at
the frontal polar region [t (34) = −3.086, p= .004]. A 2×2
ANOVA with Group as the between subjects factor and
Laterality (TP9, TP10) as the within groups factor also
revealed a significant group difference over temporo-
parietal areas [F (1, 34) = 6.323, p=.017]. Follow up inde-
pendent t-tests revealed reduced MMN amplitude in the
at risk group over the right temporo-parietal electrode
TP10 in comparison to the Control group [t (34) =
2.660, p=.012].
For latency measures, a 2×4 ANOVA with Group (At
risk, Controls) as the between subjects factor with Re-
gion (frontal polar, frontal, frontocentral and central) as
the within groups factor was also conducted. A main ef-
fect of Region [F (3, 102) = 5.085, p = .006] was found
which demonstrated delayed processing over frontal
polar regions. The groups did not differ in MMN latency
in any region. A 2×2 ANOVA was conducted for Lat-
erality (TP9, TP10) and Group which revealed no signifi-
cant differences. A 2×2 ANOVA was conducted on P3a
mean amplitude comparing Group (At risk, Controls)
and Region (Frontal (Fz) and Central (Cz)). A main ef-
fect of Region [F (1, 34) = 14.252, p = .001] revealed
increased frontal activity compared to central regions.
P3a latency was also analysed and a main effect of Re-
gion [F (1, 34) = 6.228, p = .018] showed shorter latency
in the frontal region in comparison to the central region.
The groups did not differ on P3a amplitude or latency.
Discussion
Adolescents reporting psychotic symptoms from a com-
munity sample exhibit deficits in preattentive auditory
change detection as indexed by reduced MMN ampli-
tude compared to a control group. This finding is
consistent with studies of patients with chronic schizo-
phrenia [2,15,47], first episode patients [9,16] and
individuals in the ultra high risk or prodromal stage
[1,17,19,48] which have reported reduced MMN ampli-
tude over frontocentral regions. MMN amplitude was
also reduced at mastoid electrode sites which is consist-
ent with a previous study in first episode patients [9].
However, this finding is the first to be reported in
individuals at risk for psychosis.
The results of the current study support the evidence
suggesting that reduced MMN in response to duration
Table 1 MMN/P3a mean amplitude (μV) and standard
deviation values at frontal and temporal electrodes for
each group
##Electrode Controls At-risk ES d (r)
Location Mean (SD) Mean (SD) (At-risk vs. controls)
FP1 −1.24 μV (1.11) −0.60 μV (1.07) −0.59 (−0.28)
FPz −1.40 μV (1.17) −0.38 μV (1.40) −0.79 (−0.37)
FP2 −1.24 μV (1.15) −0.32 μV (1.90) −0.59 (−0.28)
F1 −1.37 μV (0.87) −0.79 μV (0.81) −0.69 (−0.33)
Fz −1.09 μV (0.87) −0.70 μV (1.20) −0.37 (−0.19)
F2 −1.03 μV (1.05) −0.80 μV (1.30) −0.19 (−0.10)
FC1 −0.91 μV (0.59) −0.67 μV (0.72) −0.36 (−0.18)
FCz −0.62 μV (0.73) −0.52 μV (0.96) −0.12 (−0.06)
FC2 −0.60 μV (0.76) −0.63 μV (1.09) 0.03 (0.02)
C3 −1.56 μV (1.29) −0.93 μV (0.98) −0.55 (−0.27)
Cz −0.19 μV (0.66) −0.22 μV (0.80) 0.04 (0.02)
C4 −0.17 μV (0.74) −0.42 μV (0.92) 0.30 (0.15)
TP9 1.69 μV (1.08) 0.93 μV (1.69) 0.54 (0.26)
TP10 1.55 μV (1.14) 0.71 μV (1.12) 0.74 (0.35)
P3a Fz 1.47 μV (1.00) 1.25 μV (1.34) 0.19 (0.09)
P3a Cz 0.29 μV (0.84) 0.81 μV (0.96) −0.58 (−0.28)
Note: Effect sizes are calculated as the standardised mean differences:
ES = (Mean of at-risk group minus the mean of controls)/Pooled SD.
‘μV’ = microvolts.
Table 2 The means and standard deviations of demographic variables overall and for each group
Variable Overall At-risk Controls F & P values P<0.05
(N=14) (N=22)
Age (Mean Years/SD) 11.48 (.60) 11.57 (.85) 11.41 (.50) X2=6.166, df=2, p=.104
Sex (Male; Female) 16 M; 20 F 8 M; 6 F 8 M; 14 F X2=.773, df=1, p=.379
Handedness 35 R; 5 L 13 R; 1 L 19 R; 3 L X2=.000, df=1, p=1.000
SES (N=Professional/Managerial & Other) N=34; 6 Other N=11; 3 Other N=19; 2 Other X2=.255, df=1, p=.613
Note: SES=Socio-economic Status; Number of participant’s parents occupations in Professional/Managerial or Other roles.
Murphy et al. BMC Psychiatry 2013, 13:45 Page 5 of 7
http://www.biomedcentral.com/1471-244X/13/45
deviants may represent a potential biomarker candidate
for psychosis. Duration deviant paradigms yield more
consistent results and appear to be more sensitive to
deficits than frequency deviants. Umbricht and Krljes
[49] revealed that the effect size between patients and
controls for duration deviants was 40% larger than that
for frequency deviants. Deficient MMN in response to a
frequency deviant is usually observed in chronic patients
and is associated with illness progression and functional
status, whereas impaired duration MMN has been
proposed as a possible trait marker for schizophrenia
[9,50].
P3a amplitude or latency was unaffected in the at-risk
group as no group differences were found for this com-
ponent. Impairments in MMN accompanied by an un-
affected P3a may suggest a subtle disruption in the
initial automatic detection of change in the auditory en-
vironment that is not sufficiently impaired to affect the
subsequent attention orienting response. There were no
group differences in MMN latency, which supports pre-
vious studies reporting a lack of MMN latency
differences in chronic patients with schizophrenia
compared to controls [29].
Some limitations of this study must be addressed. In
view of the relatively small sample size replication of our
findings in larger samples of individuals with psychotic
symptoms or prodromal syndromes will be required.
The lack of longitudinal follow up data limits the ability
to draw conclusions regarding the predictive value of
reduced MMN amplitude as a marker of vulnerability to
psychosis. Follow up studies will elucidate whether the
MMN can distinguish between those who develop
psychosis or another psychiatric disorder from those
who do not. Nonetheless, this study provides important
information regarding the utility of the mismatch nega-
tivity as a potential biomarker for a broader psychosis
phenotype and demonstrates the value of this population
in terms of understanding the underlying pathophysi-
ology of psychosis in pre-disease, pre-medication, com-
munity based group. The community based approach of
the current work also helps to address limitations of
clinic based research, including clinically presenting
ultra high risk patients, which may be confounded by
pre-existing illness related biological changes, with re-
sultant identification of state rather than trait markers
for psychosis Belger et al., [51].
Conclusions
In summary, our results demonstrate that adolescents
with psychotic symptoms from the general population
are characterised by a reduction in duration MMN amp-
litude at frontal and temporal areas compared to a con-
trol group. These findings are the first to be shown in
adolescents from a community sample experiencing
nonclinical psychotic symptoms indicating that neurobio-
logical changes, particularly impairments in preattentive
auditory processing, are evident long before illness onset
during the risk period.
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